CY1120408T1 - Βελτιωμενες φαρμακοτεχνικες μορφες - Google Patents

Βελτιωμενες φαρμακοτεχνικες μορφες

Info

Publication number
CY1120408T1
CY1120408T1 CY20181100697T CY181100697T CY1120408T1 CY 1120408 T1 CY1120408 T1 CY 1120408T1 CY 20181100697 T CY20181100697 T CY 20181100697T CY 181100697 T CY181100697 T CY 181100697T CY 1120408 T1 CY1120408 T1 CY 1120408T1
Authority
CY
Cyprus
Prior art keywords
improved pharmaceutical
pharmaceutical forms
improved
mixtures
contain
Prior art date
Application number
CY20181100697T
Other languages
English (en)
Inventor
Laman Alani
Soumojeet Ghosh
Original Assignee
Abbvie Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23936923&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1120408(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc. filed Critical Abbvie Inc.
Publication of CY1120408T1 publication Critical patent/CY1120408T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Παρέχονται βελτιωμένες φαρμακευτικές συνθέσεις οι οποίες περιέχουν μία ή περισσότερες διαλυτοποιημένες ενώσεις αναστολής της πρωτεάσης του HIV που διαθέτουν βελτιωμένες ιδιότητες διαλυτότητας σε λιπαρό οξύ μέσης και/ή μακράς αλύσου ή μίγματα αυτών, μία φαρμακευτικώς αποδεκτή αλκοόλη και ύδωρ.
CY20181100697T 2000-01-19 2018-07-03 Βελτιωμενες φαρμακοτεχνικες μορφες CY1120408T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48773900A 2000-01-19 2000-01-19
EP00982360A EP1248600B1 (en) 2000-01-19 2000-12-01 Improved hiv protease inhibitors pharmaceutical formulations
EP07121429A EP1917958B1 (en) 2000-01-19 2000-12-01 Improved HIV protease inhibitors pharmaceutical formulations

Publications (1)

Publication Number Publication Date
CY1120408T1 true CY1120408T1 (el) 2019-07-10

Family

ID=23936923

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20081100740T CY1108197T1 (el) 2000-01-19 2008-07-16 Βελτιωμενες φαρμακευτικες συνταγοποιησεις αναστολεων πρωτεασης hiv
CY20121100711T CY1112995T1 (el) 2000-01-19 2012-08-07 Βελτιωμενες φαρμακοτεχνικες μορφες αναστολεων πρωτεασης ηιv
CY20181100697T CY1120408T1 (el) 2000-01-19 2018-07-03 Βελτιωμενες φαρμακοτεχνικες μορφες

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CY20081100740T CY1108197T1 (el) 2000-01-19 2008-07-16 Βελτιωμενες φαρμακευτικες συνταγοποιησεις αναστολεων πρωτεασης hiv
CY20121100711T CY1112995T1 (el) 2000-01-19 2012-08-07 Βελτιωμενες φαρμακοτεχνικες μορφες αναστολεων πρωτεασης ηιv

Country Status (26)

Country Link
EP (3) EP1248600B1 (el)
JP (1) JP4769400B2 (el)
KR (1) KR100861885B1 (el)
CN (1) CN100536833C (el)
AT (1) ATE395049T1 (el)
AU (2) AU1940501A (el)
BG (1) BG66112B1 (el)
BR (1) BR0011864A (el)
CA (1) CA2395987C (el)
CY (3) CY1108197T1 (el)
CZ (1) CZ304118B6 (el)
DE (1) DE60038899D1 (el)
DK (3) DK1917958T3 (el)
ES (3) ES2387579T3 (el)
HK (1) HK1120213A1 (el)
HU (1) HU229778B1 (el)
IL (2) IL150265A0 (el)
MX (1) MXPA02007097A (el)
NO (1) NO331400B1 (el)
NZ (1) NZ519724A (el)
PT (3) PT1917958E (el)
SI (3) SI2269591T1 (el)
SK (1) SK287143B6 (el)
TR (1) TR201809435T4 (el)
WO (1) WO2001052821A1 (el)
ZA (1) ZA200205109B (el)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034119A2 (en) 1999-11-12 2001-05-17 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
GB0615211D0 (en) * 2006-07-31 2006-09-06 Ge Healthcare Uk Ltd Asymmetric flouro-substituted polymethine dyes
US20110224435A1 (en) * 2007-08-07 2011-09-15 Ranbaxy Laboratories Limited Process for preparation of amorphous lopinavir
WO2012164575A2 (en) 2011-05-27 2012-12-06 Hetero Research Foundation Amorphous ritonavir co-precipitated
GB201808564D0 (en) 2018-05-24 2018-07-11 Douglas Pharmaceuticals Ltd Treatments

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US594836A (en) * 1897-11-30 Corner-brace
US5354866A (en) 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
US5696270A (en) 1989-05-23 1997-12-09 Abbott Laboratories Intermediate for making retroviral protease inhibiting compounds
GB8927913D0 (en) 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
DK0813867T3 (da) 1990-11-19 2005-10-03 Monsanto Co Retrovirale proteaseinhibitorer
CA2056911C (en) 1990-12-11 1998-09-22 Yuuichi Nagano Hiv protease inhibitors
EP0532466A3 (en) 1991-09-12 1993-06-16 Ciba-Geigy Ag Derivatives of 5-amino-4-hydroxy-hexanoic acid and their therapeutical use
EP0607334B1 (en) 1991-10-11 1997-07-30 The Du Pont Merck Pharmaceutical Company Cyclic ureas and analogues useful as retroviral protease inhibitiors
EP0541168B1 (en) 1991-11-08 1998-03-11 Merck & Co. Inc. HIV protease inhibitors useful for the treatment of aids
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
DE69300043T2 (de) 1992-03-13 1995-05-24 Bio Mega Boehringer Ingelheim Substituierte Pipecoline-Säurederivate als HIV-Protease-Hemmer.
AU676479B2 (en) 1992-05-20 1997-03-13 G.D. Searle & Co. Method for making intermediates useful in synthesis of retroviral protease inhibitors
US5559256A (en) 1992-07-20 1996-09-24 E. R. Squibb & Sons, Inc. Aminediol protease inhibitors
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5484926A (en) 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
CA2170020C (en) 1992-12-29 2005-08-02 Dale J. Kempf Retroviral protease inhibiting compounds
WO1995006061A1 (en) 1993-08-20 1995-03-02 G.D. Searle & Co. Retroviral protease inhibitors and combinations thereof
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
US5491253A (en) 1993-10-22 1996-02-13 Abbott Laboratories Process for the preparation of a substituted 2,5-diamino-3-hydroxyhexane
IL111991A (en) * 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
IL129871A (en) 1994-05-06 2003-11-23 Pharmacia & Upjohn Inc Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections
US5567823A (en) 1995-06-06 1996-10-22 Abbott Laboratories Process for the preparation of an HIV protease inhibiting compound
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
CA2238977A1 (en) * 1995-12-13 1997-06-19 Abbott Laboratories Retroviral protease inhibiting compounds
US6160122A (en) 1996-06-28 2000-12-12 Abbott Laboratories Process for the preparation of a disubstituted thiazole
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
CA2371109C (en) * 1999-06-04 2011-04-26 Laman A. Alani Improved pharmaceutical formulations

Also Published As

Publication number Publication date
HUP0302070A3 (en) 2007-02-28
SK11102002A3 (sk) 2002-12-03
TR201809435T4 (tr) 2018-07-23
AU2006235895A1 (en) 2006-11-30
CZ20022663A3 (cs) 2002-11-13
NO331400B1 (no) 2011-12-19
SI1248600T1 (sl) 2008-08-31
NZ519724A (en) 2004-07-30
EP1248600B1 (en) 2008-05-14
PT1917958E (pt) 2012-08-16
KR20020082210A (ko) 2002-10-30
CN100536833C (zh) 2009-09-09
SK287143B6 (sk) 2010-01-07
SI2269591T1 (en) 2018-08-31
EP1917958B1 (en) 2012-06-13
HK1120213A1 (en) 2009-03-27
NO20023455D0 (no) 2002-07-18
HUP0302070A2 (hu) 2003-09-29
PT1248600E (pt) 2008-08-25
EP2269591A3 (en) 2011-07-27
ES2387579T3 (es) 2012-09-26
JP4769400B2 (ja) 2011-09-07
CA2395987A1 (en) 2001-07-26
EP2269591A2 (en) 2011-01-05
EP1917958A3 (en) 2008-08-27
WO2001052821A1 (en) 2001-07-26
DK1248600T3 (da) 2008-09-08
ES2676151T3 (es) 2018-07-17
AU1940501A (en) 2001-07-31
BR0011864A (pt) 2004-07-20
DE60038899D1 (de) 2008-06-26
BG66112B1 (bg) 2011-05-31
MXPA02007097A (es) 2003-01-28
ZA200205109B (en) 2003-10-31
CZ304118B6 (cs) 2013-11-06
DK1917958T3 (da) 2012-09-24
KR100861885B1 (ko) 2008-10-09
CN1424907A (zh) 2003-06-18
AU2006235895B2 (en) 2009-08-13
PL361396A1 (en) 2004-10-04
NO20023455L (no) 2002-09-18
ES2304990T3 (es) 2008-11-01
EP1917958A2 (en) 2008-05-07
HU229778B1 (hu) 2014-07-28
EP2269591B1 (en) 2018-04-04
IL150265A0 (en) 2002-12-01
JP2003533435A (ja) 2003-11-11
BG106976A (bg) 2003-05-30
CY1112995T1 (el) 2016-04-13
PT2269591T (pt) 2018-07-09
IL150265A (en) 2015-02-26
ATE395049T1 (de) 2008-05-15
CY1108197T1 (el) 2014-02-12
SI1917958T1 (sl) 2012-10-30
EP1248600A1 (en) 2002-10-16
CA2395987C (en) 2009-12-22
DK2269591T3 (en) 2018-07-16

Similar Documents

Publication Publication Date Title
CY1120408T1 (el) Βελτιωμενες φαρμακοτεχνικες μορφες
CY1105237T1 (el) Βελτιωμεναι φαρμακευτικαι διαμορφωσεις πepιλαμβανουσαι ritonavir
CY1108305T1 (el) Συνεργιστικοι συνδυασμοι που περιλαμβανουν αναστολεα ρενινης για καρδιαγγειακες παθησεις
ITTO20010005A1 (it) Formulazione farmaceutica.
PA8518801A1 (es) Derivados de 2-aminocarbonil-9h-purina
FI20105657A (fi) Farmaseuttisia koostumuksia
CY1108522T1 (el) Μεθοδος συνθεσης της περινδοπριλης και των φαρμακευτικως αποδεκτων αλατων της
ITMI20010748A0 (it) Composizioni farmaceutiche
NO20024891D0 (no) Farmasöytiske sammensetninger
NO20032613D0 (no) Farmasöytisk sammensetning som har en forbedret vannopplöselighet
NO20031185L (no) Fusjonsprotein fra antistoff-cytokin-cytokininhibitor (selektokin) for anvendelse som mål-pesifikt prolegemiddel
NO20031095D0 (no) Farmasöytiske sammensetninger
IT1318401B1 (it) Derivati di n-desacetiltiocolchicina e composizioni farmaceutiche cheli contengono.
AR028537A1 (es) Hidrazidas y alcoxiamidas inhibidoras de la angiogénesis
MXPA03001857A (es) Composicones medicinales.
IT1318654B1 (it) Composizioni farmaceutiche comprendenti agenti antiinfiammatori e lorousi.
ECSP003602A (es) PRODUCTOS DE LA DROGA ß- CARBOLINE
ECSP982538A (es) Formulaciones farmaceuticas que contienen variconazol
NL1018306A1 (nl) Dobbelmachine.
ES1047600Y (es) Pieza de doble retencion para dentaduras parciales.
ITBO20000454A0 (it) Anello componibile .
ES1047745Y (es) Expositor colgante mejorado.
GT199800008A (es) Procedimiento para la preparacion de un derivado de tetrahidropiridina.
DZ3205A1 (fr) La pilule stérilisante.